Abstract
The prostate has the highest level of polyamines among all tissues, and it is the only tissue in which polyamines are purposely synthesized for export. It has been suggested that the high local polyamine concentrations suppress cell growth of primary prostatic carcinomas and that this growth control is lost when cancer cells metastasize. It has also been shown that the sensitivity to polyamine-induced growth arrest correlates with antizyme induction in prostate carcinoma cell lines. In this study, we evaluated the sensitivity of poorly metastatic (LNCaP) and highly metastatic (DU145) prostate cancer cell lines to conditional antizyme 1 over-expression. Antizyme 1 induction resulted in a marked loss of ODC activity and polyamine uptake in both cell lines. However, the proliferation of LNCaP cells was repressed by antizyme 1 induction, whereas the proliferation of DU 145 cells was not affected. Neither cell line showed any reduction in polyamine pools after manipulation nor did polyamine addition into the medium save the LNCaP cells from the growth retardation. The growth inhibition of LNCaP cells was accompanied by accumulation of cells in the G1 phase and depletion of cyclin E1 protein. These results confirm that different prostate cancer cell lines show diverse sensitivities to antizyme 1 which may not be directly polyamine related. The high gene transfer capacity of the used lentiviral vector makes the present approach a useful tool to study the therapeutic potential of antizyme 1 both in cell cultures and experimental animals.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00726-011-1033-9/MediaObjects/726_2011_1033_Fig1_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00726-011-1033-9/MediaObjects/726_2011_1033_Fig2_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00726-011-1033-9/MediaObjects/726_2011_1033_Fig3_HTML.gif)
Similar content being viewed by others
Abbreviations
- AZ:
-
Antizyme
- AZIn:
-
Antizyme inhibitor
- DFMO:
-
Difluoromethylornithine
- LTR:
-
Long terminal repeat
- MOI:
-
Multiplicity of infection
- ODC:
-
Ornithine decarboxylase
- SIN:
-
Self inactivating
References
Alm K, Oredsson S (2009) Cells and polyamines do it cyclically. Essays Biochem 46:63–76
Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K (2007) Current protocols in molecular biology. Wiley, USA
Crozat A, Palvimo J, Julkunen M, Janne O (1992) Comparison of androgen regulation of ornithine decarboxylase and S- adenosylmethionine decarboxylase gene expression in rodent kidney and accessory sex organs. Endocrinology 130:1131–1144
Devlin HL, Mudryj M (2009) Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett 274:177–186
Feith DJ, Shantz LM, Pegg AE (2001) Targeted antizyme expression in the skin of transgenic mice reduces tumor promoter induction of ornithine decarboxylase and decreases sensitivity to chemical carcinogenesis. Cancer Res 61:6073–6081
Gupta S, Ahmad N, Marengo SR, MacLennan GT, Greenberg NM, Mukhtar H (2000) Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice. Cancer Res 60:5125–5133
Hyvönen T, Keinanen TA, Khomutov AR, Khomutov RM, Eloranta TO (1992) Monitoring of the uptake and metabolism of aminooxy analogues of polyamines in cultured cells by high-performance liquid chromatography. J Chromatogr 574:17–21
Igarashi K, Kashiwagi K (2010) Modulation of cellular function by polyamines. Int J Biochem Cell Biol 42:39–51
Iwata S, Sato Y, Asada M, Takagi M, Tsujimoto A, Inaba T, Yamada T, Sakamoto S, Yata J, Shimogori T, Igarashi K, Mizutani S (1999) Anti-tumor activity of antizyme which targets the ornithine decarboxylase (ODC) required for cell growth and transformation. Oncogene 18:165–172
Janne J, Williams-Ashman HG (1971) On the purification of l-ornithine decarboxylase from rat prostate and effects of thiol compounds on the enzyme. J Biol Chem 246:1725–1732
Kahana C (2007) Ubiquitin dependent and independent protein degradation in the regulation of cellular polyamines. Amino Acids 33:225–230
Kahana C (2009) Antizyme and antizyme inhibitor, a regulatory tango. Cell Mol Life Sci 66:2479–2488
Kankare K, Uusi-Oukari M, Janne OA (1997) Structure, organization and expression of the mouse ornithine decarboxylase antizyme gene. Biochem J 324:807–813
Koike C, Chao DT, Zetter BR (1999) Sensitivity to polyamine-induced growth arrest correlates with antizyme induction in prostate carcinoma cells. Cancer Res 59:6109–6112
Kramer DL, Vujcic S, Diegelman P, Alderfer J, Miller JT, Black JD, Bergeron RJ, Porter CW (1999) Polyamine analogue induction of the p53–p21WAF1/CIP1-Rb pathway and G1 arrest in human melanoma cells. Cancer Res 15:1278–1286
Lee JT, Lehman BD, Terrian DM et al (2008) Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 7:1745–1762
Lopez-Contreras AJ, Ramos-Molina B, Cremades A, Penafiel R (2010) Antizyme inhibitor 2: molecular, cellular and physiological aspects. Amino Acids 38:603–611
Mi Z, Kramer D, Miller J, Bergeron R, Bernacki R, Porter C (1998) Human prostatic carcinoma cell lines display altered regulation of polyamine transport in response to polyamine analogs and inhibitors. Prostate 34:51–60
Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM (1998) Development of a self-inactivating lentivirus vector. J Virol 72:8150–8157
Newman RM, Mobascher A, Mangold U, Koike C, Diah S, Schmidt M, Finley D, Zetter BR (2004) Antizyme targets cyclin D1 for degradation: a novel mechanism for cell growth repression. J Biol Chem 23:23
Prather RS, Boquest AC, Day BN (1999) Cell cycle analysis of cultured porcine mammary cells. Cloning 1:17–24
Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM (2002) Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 62:4427–4433
Schipper RG, Romijn JC, Cuijpers VM, Verhofstad AA (2003) Polyamines and prostatic cancer. Biochem Soc Trans 31:375–380
Shantz LM, Levin VA (2007) Regulation of ornithine decarboxylase during oncogenic transformation: mechanisms and therapeutic potential. Amino Acids 33:213–223
Shin K-J, Wall EA, Zavzavadjian JR, Santat LA, Liu J, Hwang J-I, Rebres R, Roach T, Seaman W, Simon MI, Fraser IDC (2006) A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression. PNAS 103:13759–13764
Simoneau AR, Gerner EW, Nagle R, Ziogas A, Fujikawa-Brooks S, Yerushalmi H, Ahlering TE, Lieberman R, McLaren CE, Anton-Culver H, Meyskens FL Jr (2008) The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev 17:292–299
Sinn PL, Sauter SL, McCray PB Jr (2005) Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors—design, biosafety, and production. Gene Ther 12:1089–1098
Young L, Salomon R, Au W, Allan C, Russell P, Dong Q (2006) Ornithine decarboxylase (ODC) expression pattern in human prostate tissues and ODC transgenic mice. J Histochem Cytochem 54:223–229
Acknowledgments
We thank Prof. Olli Jänne for providing the mutated mouse AZ1 cDNA and the rabbit polyclonal anti-AZ1 antibody. We also thank Ms. Arja Korhonen, Anne Karppinen and Tuula Reponen for their skillful technical assistance. This work was financially supported by the Academy of Finland.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pietilä, M., Lampinen, A., Pellinen, R. et al. Inducible expression of antizyme 1 in prostate cancer cell lines after lentivirus mediated gene transfer. Amino Acids 42, 559–564 (2012). https://doi.org/10.1007/s00726-011-1033-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00726-011-1033-9